STOCK TITAN

Exelixis Inc - EXEL STOCK NEWS

Welcome to our dedicated news page for Exelixis (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exelixis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exelixis's position in the market.

Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) announces participation in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
conferences
-
Rhea-AI Summary
Exelixis, Inc. announced that the CABINET trial will be stopped early due to a dramatic improvement in efficacy. Cabozantinib showed substantial improvement in patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. Detailed findings will be presented at an upcoming medical meeting and discussed with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Exelixis appoints Amy Peterson as EVP, Product Development & Medical Affairs, and Chief Medical Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
The CONTACT-02 trial showed that cabozantinib in combination with atezolizumab improved progression-free survival in patients with metastatic castration-resistant prostate cancer. A trend towards improvement in overall survival was also observed. The trial will continue to the next analysis of overall survival. The safety profile of the combination was consistent with known profiles. Positive findings from the trial provide a potential new treatment option for this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
-
Rhea-AI Summary
Exelixis reports Q2 2023 financial results with total revenues of $469.8 million and GAAP diluted EPS of $0.25. CABOMETYX continues to be the leading tyrosine kinase inhibitor for renal cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
-
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) settles patent litigation with Teva Pharmaceuticals, granting Teva a license to market a generic version of CABOMETYX in the U.S. from January 1, 2031, pending FDA approval. The settlement also terminates ongoing Hatch-Waxman litigation between the two companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
Exelixis Inc

Nasdaq:EXEL

EXEL Rankings

EXEL Stock Data

6.92B
255.76M
2.34%
88.14%
2.25%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Alameda

About EXEL

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.